AstraZeneca gets CDSCO approval for preventive therapy for respiratory syncytial virus

This innovative therapy is indicated for prevention of serious lower respiratory tract disease requiring hospitalisation caused by Respiratory Syncytial Virus (RSV) in children at high risk of RSV disease, it added. RSV is a public health challenge faced across the globe today and is the second most common cause of death in children under 1 year of age.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r2auDAM
via IFTTT